Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZD-1656 是口服有效的葡萄糖激酶选择性激活剂,EC50为 60 nM。AZD1656在2 型糖尿病中有研究的价值。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 752 | 现货 | ||
5 mg | ¥ 1,860 | 现货 | ||
10 mg | ¥ 2,980 | 现货 | ||
25 mg | ¥ 5,930 | 现货 | ||
50 mg | ¥ 7,880 | 5日内发货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,960 | 现货 |
产品描述 | AZD-1656 is a glucokinase activator (GKA) that can cause dose-limiting hypoglycemia in normal animals used in embryofetal development studies and type 2 diabetes. |
靶点活性 | glucokinase:60 nM (EC50) |
体内活性 | The gkdel/wt mouse was used as an alternative rodent strain for embryofetal development studies with AZD-1656. Heterozygous global knockout gkdel/wt females were dosed with 20, 50, or 130 mg/kg/day of AZD-1656 or vehicle for a minimum of 14 consecutive days before mating with wild-type males and throughout organogenesis. Maternal effects were confined to slightly reduced food consumption, reduced body weight gain, and the pharmacologic effect of decreased plasma glucose. Fetuses were genotyped. Fetal weights at the high dose were slightly reduced but there was no effect on fetal survival. There were two specificmajormalformations, omphalocele and right-sided aortic arch, with increased fetal incidence in mid- and high-dose fetuses (e.g., omphalocele fetal incidence of 0.6, 0.7, 4.6, and 2% across the dose groups) plus increased incidences of minor abnormalities and variants indicative of either delayed or disturbed development. Fetal weight and abnormalities were unaffected by fetal genotype. The fetal effects are considered hypoglycemia related. There was no effect on embryofetal survival in the gkdel/wt mouse at AZD-1656 exposures[1]. |
别名 | AZD 1656 |
分子量 | 478.5 |
分子式 | C24H26N6O5 |
CAS No. | 919783-22-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (522.47 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0899 mL | 10.4493 mL | 20.8986 mL | 52.2466 mL |
5 mM | 0.418 mL | 2.0899 mL | 4.1797 mL | 10.4493 mL | |
10 mM | 0.209 mL | 1.0449 mL | 2.0899 mL | 5.2247 mL | |
20 mM | 0.1045 mL | 0.5225 mL | 1.0449 mL | 2.6123 mL | |
50 mM | 0.0418 mL | 0.209 mL | 0.418 mL | 1.0449 mL | |
100 mM | 0.0209 mL | 0.1045 mL | 0.209 mL | 0.5225 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AZD-1656 919783-22-5 Metabolism Glucokinase Hexokinase IV AZD1656 G6pc G6P ChREBP-β hypoglycemia AZD 1656 inhibit Inhibitor Hexokinase D epinephrine glucagon antihyperglycemic inhibitor